Related by context. All words. (Click for frequent words.) 66 metastatic cancer 65 metastatic lung cancer 65 metastatic renal cell carcinoma 65 HER2 positive breast cancer 64 carcinoid cancer 64 malignant pleural mesothelioma 64 nonsmall cell lung cancer 64 leukemia AML 64 multiple myeloma 64 metastatic colorectal cancer 64 bevacizumab Avastin 64 metastatic kidney 64 gastrointestinal stromal tumors 63 pancreatic NET 63 cisplatin chemotherapy 63 metastatic breast cancer 63 pancreatic adenocarcinoma 63 Metastatic breast cancer 63 unresectable stage 63 metastatic malignant melanoma 63 Gleevec imatinib 63 Glioblastoma Multiforme 63 gastrointestinal stromal tumors GIST 63 advanced NSCLC 63 metastatic melanoma 63 mRCC 63 renal cell carcinoma 63 colorectal cancer 63 irinotecan chemotherapy 62 imatinib Gleevec 62 peritoneal cancer 62 IV metastatic melanoma 62 squamous cell cancer 62 colon cancer 62 metastatic prostate cancer 62 recurrent glioblastoma 62 gastrointestinal stromal tumor 62 idiopathic pulmonary fibrosis IPF 62 Glioblastoma 62 standard chemotherapy regimen 62 myelodysplastic syndrome MDS 62 Adjuvant chemotherapy 61 fallopian tube carcinoma 61 solid tumors 61 Trastuzumab 61 pleural mesothelioma 61 glioblastoma 61 glioblastoma multiforme GBM 61 cancer 61 standard chemotherapy regimens 61 recurrent glioblastoma multiforme 61 chronic lymphocytic leukemia 61 cetuximab Erbitux 61 Gleevec imatinib mesylate 61 hormonal therapies 61 HER2 positive 61 bevacizumab Avastin ® 61 Hodgkin lymphoma NHL 61 sorafenib 61 ovarian cancer 61 chemotherapy regimens 61 Irinotecan 61 neuroendocrine tumors 61 relapsed leukemia 61 NSCLC 61 chronic myelogenous leukemia CML 61 HER2 positive metastatic breast 61 gefitinib Iressa 61 Velcade bortezomib 61 SCCHN 61 tyrosine kinase inhibitors TKIs 61 melanoma 61 Doxil ® 61 colorectal cancer liver metastases 60 Cisplatin 60 mycosis fungoides 60 metastatic disease 60 trabectedin 60 Glioblastoma multiforme GBM 60 temsirolimus 60 gastrointestinal stromal tumor GIST 60 gemcitabine 60 acute leukemias 60 gemcitabine Gemzar 60 prostate cancer HRPC 60 Aflibercept 60 carcinoid tumors 60 gastric cancer 60 docetaxel chemotherapy 60 Surgical resection 60 gemcitabine chemotherapy 60 IV NSCLC 60 differentiated thyroid 60 medullary thyroid cancer 60 Torisel 60 Herceptin trastuzumab 60 relapsed multiple myeloma 60 chemotherapeutic regimen 60 superficial bladder cancer 60 thymic carcinoma 60 hematological malignancy 60 erlotinib Tarceva ® 60 recurrent NSCLC 60 prostate cancer CRPC 60 chemotherapy 60 Pemetrexed 60 EGFR inhibitors 60 cytotoxic chemotherapy 60 pancreatic cancer 60 indolent NHL 60 daunorubicin 60 sorafenib Nexavar ® 60 ixabepilone 60 cetuximab 60 Metastatic melanoma 60 Camptosar ® 60 vinorelbine 60 lupus nephritis 59 dacarbazine 59 Cytoxan 59 metastatic colorectal 59 sorafenib Nexavar 59 metastatic bladder 59 5-FU/LV 59 squamous cell carcinoma SCC 59 Glioblastoma Multiforme GBM 59 pegylated liposomal doxorubicin 59 Rituximab 59 cilengitide 59 taxane chemotherapy 59 Acute Myelogenous Leukemia 59 Nexavar sorafenib 59 systemic lupus erythematosus 59 Zolinza 59 metastatic RCC 59 imatinib Gleevec ® 59 metastatic GIST 59 lymphoma 59 leukemia ALL 59 Yervoy 59 anticancer therapy 59 mCRC 59 chemotherapy cisplatin 59 gastrointestinal cancers 59 metastatic 59 Glioblastoma multiforme 59 metastatic renal cell 59 refractory multiple myeloma 59 lapatinib Tykerb 59 thalidomide Thalomid 59 carboplatin paclitaxel 59 tyrosine kinase inhibitors 59 Mantle Cell Lymphoma 59 chemotherapies 59 leukemia CLL 59 chemotherapeutic regimens 59 chemotherapy regimen 59 CHOP chemotherapy 59 Genentech Rituxan 59 prostate cancer mCRPC 59 Bevacizumab 59 Bortezomib 59 vinca alkaloids 59 decitabine 59 taxanes 59 palliative radiotherapy 59 chronic lymphocytic leukemia CLL 59 5 fluorouracil leucovorin 58 castration resistant prostate cancer 58 pancreatic cancers 58 radiofrequency ablation RFA 58 trastuzumab Herceptin 58 ABVD 58 squamous cell cancers 58 docetaxel Taxotere ® 58 cetuximab Erbitux ® 58 colorectal liver metastases 58 Vectibix 58 follicular lymphoma 58 cediranib 58 KRAS wild 58 pancreatic carcinoma 58 Hepatocellular Carcinoma HCC 58 chronic myeloid leukemia CML 58 nonmelanoma skin cancers 58 paclitaxel Taxol 58 myelodysplastic syndrome 58 OncoVEX GM CSF 58 unresectable 58 sorafenib tablets 58 basal cell carcinoma BCC 58 invasive candidiasis 58 taxotere 58 sunitinib 58 chlorambucil 58 cholangiocarcinoma 58 Metastatic 58 hormone refractory prostate cancer 58 non squamous 58 relapsed ovarian cancer 58 Cholangiocarcinoma 58 liver cancer 58 stage IIIB IV 58 IV melanoma 58 angiosarcoma 58 FOLFIRI 58 pazopanib 58 metastatic gastric 58 Jevtana 58 multiple myeloma MM 58 CYT# potent vascular disrupting 58 metastatic castration resistant 58 Gleevec resistant 58 fluorouracil 58 cancers 58 PSMA ADC 58 non squamous NSCLC 58 peritoneal carcinomatosis 58 cabazitaxel 58 resectable 58 interferon ribavirin 58 Amrubicin 58 Hycamtin 58 GISTs 58 follicular lymphoma FL 58 Mitomycin C 58 bleomycin 58 docetaxel Taxotere 58 erlotinib Tarceva 58 TACE 58 idarubicin 58 refractory chronic myeloid 58 Temodar ® 58 recurrent ovarian cancer 58 acute myelogenous leukemia AML 58 lung cancer 58 FOLFOX4 58 adriamycin 58 mycophenolate mofetil 58 cytoreduction 58 Waldenstrom macroglobulinemia 58 exemestane Aromasin 58 carcinoid 58 non hodgkin lymphoma 58 oral clodronate 58 imatinib resistant 58 hepatocellular cancer 58 relapsing MS 58 lung metastases 58 sarcoma 58 cytotoxic therapy 58 malignant melanoma 58 bone metastasis 58 prostate cancers 58 hepatocellular carcinoma 57 ovarian lung 57 pediatric malignancies 57 metastatic malignant 57 Mitoxantrone 57 Revlimid 57 eflornithine 57 cisplatin 57 alkylating agent 57 Fludarabine 57 trastuzumab 57 neoadjuvant therapy 57 metastatic carcinoma 57 GIST tumors 57 refractory ovarian cancer 57 chemotherapeutic drug 57 Lilly Gemzar 57 endocrine therapies 57 Doxorubicin 57 cisplatin resistant 57 metastatic hormone refractory 57 relapsed SCLC 57 mCRC patients 57 medically inoperable 57 taxol 57 metastatic cancers 57 chemoradiotherapy 57 T DM1 57 Gliadel Wafer 57 bortezomib 57 renal carcinoma 57 Myelodysplastic Syndrome 57 hormone receptor positive 57 axitinib 57 neuroendocrine cancers 57 hypophosphatasia 57 HRPC 57 recurrent glioblastoma multiforme GBM 57 endometrial hyperplasia 57 Decitabine 57 steroid prednisone 57 concurrent chemoradiation 57 FOLFOX6 57 pertuzumab 57 liver metastasis 57 transarterial chemoembolization 57 chemoradiation therapy 57 lymphocytic leukemia 57 malignant growths 57 KRAS mutations occur 57 RSR# 57 chemotherapy gemcitabine 57 intraperitoneal chemotherapy 57 erlotinib 57 Sorafenib 57 Chronic Myeloid Leukemia CML 57 Camptosar 57 stage IIIB 57 Xcytrin 57 radiation therapy SBRT 57 relapsed refractory multiple myeloma 57 Eli Lilly Gemzar 57 biliary tract cancer 57 pegylated interferon alpha 57 squamous cell 57 Tarceva erlotinib 57 brain metastases 57 Vandetanib 57 nasopharyngeal carcinoma 57 interferon therapy 57 malignancies 57 liposomal doxorubicin 57 Rituxan rituximab 57 bendamustine 57 neoadjuvant chemotherapy 57 TORISEL 57 CMV disease 57 colorectal cancer CRC 57 indolent lymphoma 57 HuMax CD4 57 autoantibody positive 57 eosinophilic pneumonia 57 pegylated interferon alfa 57 systemic scleroderma 57 Myelodysplastic Syndrome MDS 57 radiation chemoradiation 57 rituximab Rituxan 57 curative resection 57 Erlotinib 57 relapsing remitting MS RRMS 57 Chronic lymphocytic leukemia 57 dasatinib 57 Fludara 57 diffuse intrinsic pontine glioma 57 allogeneic HSCT 57 alveolar rhabdomyosarcoma 57 sunitinib malate 57 Sutent sunitinib 57 temozolomide Temodar 57 invasive aspergillosis 57 peginterferon 57 ImClone Erbitux 57 unresectable liver cancer 57 microwave hyperthermia 57 prostate cancer 57 chemotherapeutic agent 57 myelofibrosis polycythemia vera 57 docetaxel Taxotere R 57 cetuximab Erbitux R 57 gefitinib 57 Erbitux cetuximab 57 adjuvant radiation 57 FOLFOX chemotherapy 57 immunotherapeutic agent 57 hematologic disorders 57 Avastin 56 GvHD 56 docetaxel 56 Follicular Lymphoma 56 CBLC# 56 relapsing remitting multiple sclerosis 56 advanced metastatic prostate 56 Nexavar ® 56 5 fluorouracil 56 nonsquamous 56 dasatinib Sprycel 56 Sutent 56 Novartis Gleevec 56 capecitabine Xeloda 56 acute myeloid leukemia AML 56 Fludara ® 56 biliary cancer 56 ovarian carcinoma 56 doxorubicin 56 relapsed MM 56 5 Fluorouracil 56 epithelial tumors 56 antimetabolite 56 autologous transplant 56 refractory AML 56 Carboplatin 56 leiomyosarcoma 56 hepatocellular carcinoma HCC 56 pemphigus 56 relapsing remitting 56 Folfox 56 myeloid leukemia 56 topotecan 56 Burkitt Lymphoma 56 androgen independent 56 Malignant Melanoma 56 ductal breast cancer 56 breast cancer 56 stereotactic body 56 Bayer Nexavar 56 adjuvant therapy 56 bladder cancers 56 Taxotere docetaxel 56 Chronic Lymphocytic Leukemia 56 ELOXATIN 56 Alemtuzumab 56 anthracycline taxane 56 soft tissue sarcomas 56 proteasome inhibitor bortezomib 56 paclitaxel Taxol ® 56 metastatic CRC 56 Chronic Myeloid Leukemia 56 prostate adenocarcinoma 56 inoperable pancreatic cancer 56 Doxil 56 Revlimid lenalidomide 56 B CLL 56 metastatic pancreatic cancer 56 Cloretazine 56 Multiple Myeloma 56 gemcitabine carboplatin 56 intra arterial chemotherapy 56 acute promyelocytic leukemia 56 panitumumab Vectibix 56 HCV infections 56 Cremophor 56 Gemzar ® 56 trastuzumab Herceptin ® 56 ocular melanoma 56 Acute Myeloid Leukemia 56 infliximab Remicade 56 Avastin bevacizumab 56 ipilimumab 56 EGFR mutation 56 gastric cancers 56 Neulasta ® 56 Pfizer Sutent 56 BAY #-# 56 aflibercept VEGF Trap 56 chronic myelogenous leukemia 56 anaplastic 56 prostate carcinoma 56 taxane 56 castrate resistant 56 liver metastases 56 intraperitoneal therapy 56 acute myeloid leukemia 56 LHRH analogues 56 stage IIIA 56 GIST 56 Cell Lymphoma CTCL 56 colon lung 56 visilizumab 56 iniparib 56 Osteosarcoma 56 IV malignant melanoma 56 Pegylated Interferon 56 alpha interferon 56 Gefitinib 56 PLX# 56 Crizotinib 56 Alimta 56 soft tissue sarcoma 56 dasatinib Sprycel ® 56 alefacept 56 vandetanib 56 NXL# 56 Targretin 56 Advexin 56 azacytidine 56 curable cancers 56 AA amyloidosis 56 anti angiogenic agents 56 mapatumumab 56 Acute myeloid leukemia 56 chemoradiation 56 Mepact 56 angiogenesis inhibition 56 vorinostat 56 heavily pretreated 56 breast carcinomas 56 vinca alkaloid 56 Campath alemtuzumab 56 virotherapy 56 Haptoglobin 56 cytoreductive surgery 56 Acute Myeloid Leukemia AML 56 GnRH agonists 56 mTOR inhibitor 56 Paraplatin ® 56 recurrent colorectal cancer 56 imipenem 56 Novartis AG Gleevec 56 antibody MAb 56 Taxol 56 rituximab Rituxan ® 56 Annamycin 56 Allovectin 7 56 AEG# 55 Peg IFN 55 antiretroviral regimens 55 serous ovarian cancer 55 YONDELIS 55 idraparinux 55 Imatinib 55 Capecitabine 55 transplantation HCT 55 paclitaxel Taxol R 55 imatinib 55 lenalidomide Revlimid R 55 Tamibarotene 55 vemurafenib 55 EGFR TKI 55 chemotherapeutic agents 55 recurrent metastatic 55 ovarian cancers 55 paclitaxel chemotherapy 55 glioblastomas 55 Erbitux 55 interferon alfa 55 EGFr 55 PEGylated 55 locoregional 55 candidemia 55 non metastatic osteosarcoma 55 diffuse gastric 55 pemphigus vulgaris 55 cancer mCRC 55 bexarotene 55 Metastatic Colorectal Cancer 55 panitumumab 55 tumors GIST 55 FOLFIRI alone 55 preoperative chemotherapy 55 Cutaneous T 55 hormone refractory metastatic prostate 55 Bezielle 55 TEMODAL 55 tumors 55 VICTRELIS 55 taxane therapy 55 temozolomide 55 HCV infection 55 commercialize deforolimus 55 advanced unresectable 55 infusional 5-FU/LV 55 lymphoma CTCL 55 abacavir Ziagen 55 Taxotere ® 55 superficial basal cell carcinoma 55 gastroesophageal junction 55 rituximab 55 Novartis Afinitor 55 lung tumors 55 squamous 55 Everolimus 55 Proxinium TM 55 Alocrest 55 cell lymphoma CTCL 55 grade cervical intraepithelial 55 Selective Internal 55 HER2 overexpression 55 Cabazitaxel 55 CD# antibody [001] 55 calcineurin inhibitors 55 eribulin 55 PegIntron 55 adalimumab 55 cyclophosphamide chemotherapy 55 pegfilgrastim 55 complement inhibitor eculizumab 55 Pertuzumab 55 letrozole Femara 55 Acute Leukemia 55 Dabigatran 55 DFMO 55 clinically localized prostate 55 non Hodgkin lymphoma 55 biologic therapy 55 Ceplene/IL-2 55 ara C 55 CoFactor 55 Cetuximab 55 antigen PSA 55 Myelodysplastic Syndromes 55 essential thrombocythemia 55 colon tumors 55 myelofibrosis 55 Bleomycin 55 Papillary 55 Taxotere 55 cell lung cancer 55 postoperative chemotherapy 55 NovoTTF 55 amphotericin B 55 lymphoblastic lymphoma 55 Extensively drug 55 Tarceva 55 Metastatic colorectal cancer 55 SIR Spheres microspheres 55 intravenous bisphosphonates 55 glioblastoma multiforme 55 tigecycline 55 plus gemcitabine 55 Nexavar 55 basal cell cancers 55 HBeAg negative 55 BRAF inhibitor 55 unresectable tumors 55 Myelofibrosis 55 advanced hepatocellular carcinoma 55 Gastric cancer 55 Follicular lymphoma 55 metastatic lesions 55 smoldering myeloma 55 HNSCC 55 leukemia APL 55 BEACOPP 55 Hodgkin lymphoma HL 55 cyclophosphamide methotrexate 55 synovial sarcoma 55 Radiofrequency ablation 55 malignant lymphoma 55 pancreatic lung 55 Halaven 55 chemotherapy docetaxel 55 dexpramipexole 55 platinum refractory 55 operable breast cancer 55 basiliximab 55 therapeutic regimens 55 basal cell skin 55 invasive breast cancer 55 transarterial 55 adenocarcinoma 55 imatinib mesylate 55 Basal cell 55 advanced nonsquamous NSCLC 55 alpha interferons 55 osteoporotic compression fractures 55 metastatic liver 55 tesetaxel 55 Gemcitabine 55 vincristine doxorubicin 55 mTOR inhibitors 55 imatinib mesylate Gleevec 55 nasopharyngeal cancer 55 enzastaurin 55 cIAI 55 ribavirin RBV 55 esophageal cancers 55 Anthracyclines 55 nilotinib 55 colorectal lung 55 refractory CTCL 55 relapsing multiple sclerosis 55 cutaneous melanoma 55 interferon alfa 2a 55 stage IIIb 55 Eculizumab 55 placebo dexamethasone 55 galiximab 55 hormone deprivation 55 remission induction 55 chemoembolization 55 epithelial ovarian 55 Squamous 55 LHRH agonist 55 taxane refractory 55 Cyclosporine 55 pamidronate 55 thymoma 55 acute GvHD 55 melanoma tumors 55 HuLuc# 55 NNRTIs 55 Golimumab 55 Gleevec 54 nonmetastatic 54 malignant ascites 54 resistant ovarian cancer 54 mitoxantrone 54 Sezary syndrome 54 follicular NHL 54 doxorubicin Adriamycin 54 Aplidin 54 TTF Therapy 54 refractory indolent non 54 clodronate 54 azacitidine 54 Metastatic Prostate Cancer 54 ZYVOX 54 Carcinoma 54 Non Hodgkin Lymphoma 54 systemic fungal infections 54 PNET 54 breast ovarian 54 Rituxan 54 colorectal breast 54 Platinol ® 54 trastuzumab Herceptin R 54 Gemzar gemcitabine 54 GVAX 54 hormonal therapy 54 daptomycin 54 antiangiogenic therapy 54 gastric adenocarcinoma 54 anticancer agents 54 Non Hodgkins lymphoma 54 pediatric acute lymphoblastic 54 herpetic keratitis 54 Tyrosine Kinase Inhibitors 54 PREZISTA r 54 Peginterferon 54 XELOX 54 castration resistant 54 alkylating agents 54 malignancy 54 prior chemotherapy regimens 54 OHR/AVR# 54 metastatic ovarian cancer 54 MGd 54 Paraplatin ® carboplatin 54 AMN# [001] 54 cervical carcinoma 54 hematological cancers 54 luteinizing hormone releasing 54 TNF alpha antagonist 54 monoclonal antibody therapies 54 seminoma 54 sentinel lymph node biopsy 54 regorafenib 54 DOXIL 54 inoperable tumors 54 cirrhosis liver failure 54 bladder cancer 54 mitomycin C 54 Caelyx 54 kidney urologic 54 Tarvacin 54 pemetrexed 54 ZOLINZA 54 metastatic HER2 positive 54 Elotuzumab 54 ADXS# 54 assessing T DM1 54 sarcomas 54 ganetespib 54 chronic HCV 54 tyrosine kinase inhibitor 54 resistant microorganisms 54 scleroderma 54 adjuvant radiotherapy 54 Merck KGaA Erbitux 54 octreotide LAR 54 Intravenous CP 54 myelomas 54 metastatic uveal melanoma 54 basal cell nevus syndrome 54 Degarelix 54 Folotyn 54 cidofovir 54 sarcomatoid 54 intraductal 54 localized prostate cancer 54 refractory prostate cancer 54 androgen suppression therapy 54 sulfasalazine 54 non Hodgkin Lymphoma 54 leukemia 54 BRAF mutation 54 T#I [002] 54 Alessandro Riva 54 plus dexamethasone 54 lumiliximab 54 mitomycin 54 intravesical instillation 54 androgen deprivation 54 radiation therapy 54 trans retinoic acid 54 entecavir 54 metastatic testicular cancer 54 MDS AML 54 cutaneous T 54 malignant pleural mesothelioma MPM 54 Taxol paclitaxel 54 Acute Myeloid Leukaemia AML 54 protease inhibitor PI 54 adalimumab Humira 54 Hodgkin Lymphoma 54 Radioimmunotherapy 54 juvenile myelomonocytic leukemia 54 bortezomib Velcade 54 CLL 54 multimodality therapy 54 minimally symptomatic 54 non alcoholic steatohepatitis 54 pemetrexed Alimta 54 systemic ALCL 54 sipuleucel T 54 medulloblastoma malignant brain tumor 54 olaparib 54 Li Fraumeni Syndrome 54 nutlin 3a 54 Treanda 54 Hurthle cell 54 pomalidomide 54 skeletal metastases 54 evaluating tivozanib 54 bronchogenic carcinoma 54 Gleevac 54 pan HDAC inhibitor 54 squamous histology 54 xanthine oxidase inhibitor 54 lupus 54 paclitaxel carboplatin 54 Taxotere R 54 cancer immunotherapies 54 cutaneous squamous cell carcinoma 54 acute coronary syndromes ACS 54 ranibizumab Lucentis 54 Candida infection 54 PAOD 54 ATTR PN 54 myeloablative 54 proteasome inhibitor 54 pancreatic neuroendocrine tumors 54 etoposide 54 Acute lymphoblastic leukemia 54 refractory metastatic 54 Nilotinib 54 Lapatinib 54 radiolabeled TM# 54 STELARA ™ 54 Taxol ® 54 renal tumors 54 hepatitis C genotype 54 situ CIS 54 Oxaliplatin 54 investigational monoclonal antibody 54 Temsirolimus 54 Xanafide 54 hematologic malignancies 54 allogeneic stem cell 54 cyclophosphamide Cytoxan 54 Epivir 54 stage IIIb IV 54 sickest colon cancer 54 Neuvenge 54 grade gliomas 54 MIBG 54 Sunitinib 54 raloxifene Evista 54 hepatic metastases 54 uric acid lowering 54 systemic lupus erythematosus SLE 54 pancreatic tumors 54 calcineurin inhibitor 54 brain tumor glioblastoma multiforme 54 Wilm Tumor 54 echinocandin 54 DIPG 54 CD# monoclonal antibody 54 severe sepsis 54 FluCAM 54 HuMax EGFr 54 Docetaxel 54 chronic HCV infection 54 Combination therapy 54 oligodendrogliomas 54 Endometrial cancer 54 alfa 2a 54 Idiopathic Pulmonary Fibrosis 54 TKI therapy 54 immunodeficiency disorders 54 SHPT 54 doublet chemotherapy 54 amoxicillin clavulanate 54 cytotoxics 54 Anaplastic 54 MyVax R 54 prostate tumors 54 resistant hormone refractory 54 vWD 54 esophageal tumors 54 anti EGFR antibody 54 refractory APL 54 cutaneous T cell 54 IMA# 54 carcinoma 54 mucinous 54 osteosarcoma 54 relapsed CLL 54 molecularly targeted 54 PCNSL 54 IRX 2 54 TYGACIL 54 cisplatin gemcitabine 54 PARP inhibitors 54 metastatic adenocarcinoma 54 Natalizumab 54 interferon beta 1a 54 medulloblastoma 54 Pseudomonas infections 54 relapsing remitting MS 54 PEG interferon 54 carfilzomib 54 anthracyclines 54 non hodgkins lymphoma 54 HAART regimen 54 MYCN amplification 54 proteasome inhibitors 54 corticosteroid dexamethasone 54 docetaxel prednisone 53 opioid induced constipation OIC 53 S. aureus infections 53 glioblastoma tumors 53 diagnosed glioblastoma multiforme 53 cancerous polyp 53 Noxafil 53 myeloma 53 Radiation Therapy SIRT 53 colorectal carcinoma 53 HGS ETR1 53 receptor tyrosine kinase inhibitor 53 Candida infections 53 metastatic castrate resistant 53 SIR Spheres 53 immunosuppressant drug 53 Hydroxyurea 53 Multiple Myeloma MM 53 aortic dissections 53 castrate resistant prostate cancer 53 colorectal cancers 53 ovarian breast 53 Ixempra 53 hypereosinophilic syndrome 53 relapsed refractory 53 Vidaza azacitidine 53 ifosfamide 53 ductal cancer 53 Vicinium TM 53 abiraterone 53 anthracyclines taxanes 53 anti CD3 antibody 53 rFVIIa 53 metastatic neuroendocrine tumors 53 EGFR tyrosine kinase inhibitors 53 immunosuppressive therapies 53 acute leukemia 53 Taxanes 53 oxaliplatin 53 heavily pretreated patients 53 Valopicitabine 53 doxorubicin HCl liposome injection 53 angiogenesis inhibitor 53 VFEND 53 EFAPROXYN 53 prostate cancer PCa 53 hepatorenal syndrome 53 hormone refractory 53 nucleoside analogues 53 Chronic lymphocytic leukemia CLL 53 Novartis Zometa 53 Xelox 53 irinotecan 53 biologic DMARD 53 testicular cancers 53 IRESSA 53 Ceflatonin 53 aminoglycosides 53 endometrial cancers 53 Exemestane 53 paclitaxel 53 PTLD 53 Androgen deprivation therapy 53 Provenge 53 IV Busulfex 53 Severe Primary IGFD 53 TheraSphere 53 Renal cell carcinoma 53 microtubule inhibitor 53 paclitaxel cisplatin 53 KRAS mutation 53 KRAS mutant 53 hematopoietic cancers 53 interferon 53 pegylated interferon alfa 2a 53 mutated KRAS 53 figitumumab